Novel object recognition as a facile behavior test for evaluating drug effects in AβPP/PS1 Alzheimer's disease mouse model.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the AβPP/PS1 transgenic mouse model is a commonly used experimental model to mimic the pathological and cognitive impairments in AD. As a classic method to evaluate spatial learning and memory, the Morris water maze is widely applied to study the cognitive deficits in rodent AD models. However, the assay procedure is relatively complicated and requires a properly equipped environment. The novel object recognition test is a relatively simple and straightforward method to test working memory in rodents. However, whether the latter can be used as a common tool for evaluating the therapeutic effects of drugs in the AβPP/PS1 transgenic AD mouse model remains unclear. In the present study, we assessed the cognitive impairment of AβPP/PS1 AD mice with the novel object recognition test. In parallel, Morris water maze was performed and compared with the novel object recognition study. Both assays worked equally well in evaluating the cognitive defect of AβPP/PS1 mice. Furthermore, we drew similar conclusions from the novel object recognition assay as from the Morris water maze in assessing the therapeutic effects of two previously reported compounds, donepezil and naltrindole, on AD. We found the novel object recognition to be a facile assay with almost no stress to mice and think it could be used as an ideal primary screening assay to evaluate drug effects on AβPP/PS1 AD model.
Shanghai Key Laboratory of Signaling and Disease Research, Laboratory of Receptor-based Bio-medicine, School of Life Sciences and Technology, Tongji University, Shanghai, China.
Ru
R
Zhang
Guizhen
G
Xue
Shaodeng
S
Wang
Lihong
L
Zhang
Changjie
C
Shi
Xin
X
Xie
D000544:Alzheimer Disease / Q000175:diagnosis / Q000235:genetics* / Q000523:psychology*; D016564:Amyloid beta-Protein Precursor / Q000235:genetics*; D000818:Animals; D004195:Disease Models, Animal; D000077265:Donepezil; D004353:Drug Evaluation, Preclinical / Q000379:methods; D005260:Female; D006801:Humans; D007189:Indans / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009271:Naltrexone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D010364:Pattern Recognition, Visual / Q000187:drug effects; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use; D053764:Presenilin-1 / Q000235:genetics*; D011897:Random Allocation
D016564:Amyloid beta-Protein Precursor; D007189:Indans; D010880:Piperidines; D053764:Presenilin-1; D009271:Naltrexone; D000077265:Donepezil; C055382:naltrindole